Patients characteristics
| Variables | RA (n=424) | axSpA (n=145) | PsA (n=132) | SLE (n=41) | Other diseases* (n=233) |
| Age, years, mean (SD) | 60.7 (13.4) | 43.7 (12.4) | 51.3 (12.7) | 48.4 (17.6) | 56.1 (16.9) |
| Gender, male, n (%) | 137 (32.3) | 95 (65.5) | 55 (41.7) | 4 (9.8) | 64 (27.5) |
| Disease duration, years, mean (SD) | 8.6 ((9.0) | 12.0 (11.6) | 8.1 (8.9) | 10.0 (10.5) | 6.5 (11.6) |
| Prevalence of comorbidities, n (%) | 307 (72.4) | 78 (53.8) | 73 (55.3) | 26 (63.4) | 134 (57.5) |
| Rabbit risk score, mean (SD) | 4.4 (5.0) | 4.7 (2.8) | 3.3 (3.4) | 2.4 (9.4) | 4.0 (9.4) |
| Current use of bDMARDs, n (%) | 163 (38.4) | 103 (71.0) | 76 (57.6) | 9 (22.0) | 59 (25.3) |
| Physical function,† mean (SD) | 1.30 (0.76), n=355 | 4.0 (2.55), n=142 | 1.28 (0.68), n=97 | 1.12 (0.67), n=40 | 1.03 (0.69), n=211 |
| CRP (mg/dL), median (IQR) | 0.3 (0.1–0.7), n=421 | 0.2 (0.1–0.6) | 0.2 (0.1–0.7) n=131 | 0.2 (0.0–0.4) | 0.3 (0.1–0.6), n=225 |
| Screening for latent hepatitis‡, n (%) | 202 (94.4) | 104 (92.0) | 80 (93.0) | 9 (81.8) | 74 (92.5) |
| Vaccination card available, n (%) | 230 (54.2) | 76 (52.4) | 66 (50.0) | 28 (68.3) | 140 (60.1) |
| Education about vaccination, n (%) | 273 (64.4) | 101 (69.7) | 81 (61.4) | 28 (68.3) | 146 (62.7) |
| Complete pneumococcal vaccination status, n (%) | 129 (30.4) | 33 (22.8) | 26 (19.7) | 12 (29.3) | 66 (28.3) |
| Complete influenza vaccination status, n (%) | 85 (20.0) | 17 (11.7) | 20 (15.2) | 8 (19.5) | 50 (21.5) |
| Complete hepatitis B vaccination status, n (%) | 36 (8.5) | 26 (17.9) | 13 (9.8) | 10 (24.4) | 37 (15.9) |
| Vaccination score, mean (SD) | 12.33 (5.12) | 13.67 (4.83) | 12.75 (4.98) | 13.25 (3.92) | 13.17 (4.65) |
*Diseases with a small incidence like vasculitis, connective tissue disease other than SLE, periodic fever syndromes.
†Physical function was assessed with HAQ except for axSpA patients where BASFI was used.
‡In patients with previous or current bDMARD use.
axSpa, axial spondyloarthritis; BASFI, Bath Ankylosing Spondylitis Function INdex; bDMARDs, biologic disease modifying antirheumatic drugs; CRP, C reactive protein; HAQ, health assessment questionnaire; IQR, interquartile range; PsA, psoriatic arthritis; RA, rheuamtoid arthritis; SLE, systemic lupus erythematosus.